<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35260020</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>832</StartPage>
          <EndPage>843</EndPage>
          <MedlinePgn>832-843</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2046567</ELocationID>
        <Abstract>
          <AbstractText>This paper described our efforts to develop dianilinopyrimidines as novel EGFR inhibitors. All the target compounds were tested for inhibitory effects against wild type EGFR (EGFR<sup>wt</sup>) and three tumour cells, including A549, PC-3, and HepG2. Some of the compounds performed well in antitumor activities. Especially, compound <b>4c</b> 2-((2-((4-(3-fluorobenzamido)phenyl)amino)-5-(trifluoromethyl) pyrimidin-4-yl)amino)-<i>N</i>-methylthiophene-3-carboxamide showed higher anti-tumour activities than Gefitinib. The IC<sub>50</sub> values of compound <b>4c</b> against A549, PC-3, and HepG2. reached 0.56 μM, 2.46 μM, and 2.21 μM, respectively. In addition, further studies indicated that compound <b>4c</b> could induce apoptosis against A549 cells and arrest A549 cells in the G2/M phase. Molecular docking studies showed that compound <b>4c</b> could closely interact with EGFR. Generally, compound <b>4c</b> was the potential for developing into an anti-tumour drug.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yan</LastName>
            <ForeName>Longjia</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-3703-6704</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guizhou University, Guiyang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qin</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guizhou University, Guiyang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guizhou University, Guiyang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Le</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Guizhou University, Guiyang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Design</Keyword>
        <Keyword MajorTopicYN="N">EGFR</Keyword>
        <Keyword MajorTopicYN="N">antitumor</Keyword>
        <Keyword MajorTopicYN="N">inhibitor</Keyword>
        <Keyword MajorTopicYN="N">synthesis</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35260020</ArticleId>
        <ArticleId IdType="pmc">PMC8920385</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2046567</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Riihimaki M, Hemminki A, Fallah M, et al. . 
Metastatic sites and survival in lung cancer. Lung Cancer
2014;86:78–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25130083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanana P.. 
Lung cancer: biology and treatment options. Biochim Biophys Acta
2015;1856:189–210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4663145</ArticleId>
            <ArticleId IdType="pubmed">26297204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Sanea MM, Al-Ansary GH, Elsayed ZM, et al. . 
Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells. J Enzyme Inhib Med Chem
2021;36:987–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8128204</ArticleId>
            <ArticleId IdType="pubmed">33985397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu K, Zhang C, Du T, et al. . 
Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother
2021;134:111111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33352449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rotow J, Bivona TG.. 
Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer
2017;17:637–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29068003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fennell DA, Summers Y, Cadranel J, et al. . 
Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev
2016;44:42–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26866673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrer I, Zugazagoitia J, Herbertz S, et al. . 
KRAS-Mutant non-small cell lung cancer: from biology to therapy. Lung Cancer
2018;124:53–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30268480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soliman AM, Alqahtani AS, Ghorab M.. 
Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. J Enzyme Inhib Med Chem
2019;34:1030–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6522976</ArticleId>
            <ArticleId IdType="pubmed">31074303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milik SN, Lasheen DS, Serya RAT, et al. . 
How to train your inhibitor: design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Eur J Med Chem
2017;142:131–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28754471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh SS, Mattheolabakis G, Gu X, et al. . 
A grafted peptidomimetic for EGFR heterodimerization inhibition: implications in NSCLC models. Eur J Med Chem
2021;216:113312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8044046</ArticleId>
            <ArticleId IdType="pubmed">33667849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ayati A, Moghimi S, Salarinejad S, et al. . 
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem
2020;99:103811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32278207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gharwan H, Groninger H.. 
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol
2016;13:209–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26718105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roskoski R. Jr., Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res
2020;152:104609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31862477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ewes WA, Elmorsy MA, El-Messery SM, et al. . 
Synthesis, biological evaluation and molecular modeling study of [1,2,4]-Triazolo[4,3-c]quinazolines: new class of EGFR-TK inhibitors. Bioorg Med Chem
2020;28:115373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32085964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Passaro A, Mok T, Peters S, et al. . 
Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, Non Exon 20 insertions, EGFR mutations. J Thorac Oncol
2021;16:764–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33333327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Girard N.
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Future Oncol
2018;14:1117–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29336166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim ES, Melosky B, Park K, et al. . 
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncol
2021;17:2395–408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33855865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Min HY, Yun HJ, Lee JS, et al. . 
Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer
2015;14:113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4453276</ArticleId>
            <ArticleId IdType="pubmed">26041671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu PC, Yang CT, Jablons DM, et al. . 
The crosstalk between Src and Hippo/YAP signaling pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers
2020;12:1361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7352956</ArticleId>
            <ArticleId IdType="pubmed">32466572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filosto S, Baston DS, Chung S, et al. . 
Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells. Mol Cancer Ther
2013;12:1579–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4370317</ArticleId>
            <ArticleId IdType="pubmed">23686837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilic T, Alberta JA, Zdunek PR, et al. . 
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res
2000;60:5143–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11016641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang S, Yin SL, Wang J, et al. . 
Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells. Molecules
2009;14:4166–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6254841</ArticleId>
            <ArticleId IdType="pubmed">19924055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Druker BJ.
STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med
2002;8:S14–S8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11927282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Wang Y, Jiao L, et al. . 
Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. Cancer Lett
2019;452:191–202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30910592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han H, Li S, Chen T, et al. . 
Targeting HER2 Exon 20 insertion-mutant lung adenocarcinoma with a Novel tyrosine kinase inhibitor mobocertinib. Cancer Res
2021;81:5311–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8530969</ArticleId>
            <ArticleId IdType="pubmed">34380634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pillonel C.
Evaluation of phenylaminopyrimidines as antifungal protein kinase inhibitors. Pest Manag Sci
2005;61:1069–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15952247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui J, Fu R, Zhou LH, et al. . 
BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. Bioorg Med Chem Lett
2013;23:2442–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23473682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ture A, Ergul M, Ergul M, et al. . 
Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids. Mol Divers
2021;25:1025–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32328961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vlasov SV, Kovalenko SM, Shynkarenko PE, et al. . 
Synthesis and antimicrobial evaluation of 3-(4-arylthieno[2,3-d]pyrimidin-2-yl)- 2H-chromen-2-ones. Heterocycl Commun
2018;24:237–40.</Citation>
        </Reference>
        <Reference>
          <Citation>Saravanan J, Mohan S, Roy JJ.. 
Synthesis of some 3-substituted amino-4,5-tetramethylene thieno[2,3-d][ 1,2,3]-triazin-4(3H)-ones as potential antimicrobial agents. Eur J Med Chem
2010;45:4365–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20579782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Wang Q, Li L, et al. . 
Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells. J Enzyme Inhib Med Chem
2021;36:1205–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8174486</ArticleId>
            <ArticleId IdType="pubmed">34074193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agnew-Francis KA, Williams CM.. 
Squaramides as bioisosteres in contemporary drug design. Chem Rev
2020;120:11616–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32930577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, Li Y, Tomkiewicz-Raulet C, et al. . 
Design, synthesis, and biological evaluation of covalent inhibitors of Focal Adhesion Kinase (FAK) against human malignant glioblastoma. J Med Chem
2020;63:12707–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33119295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sylvester PW.
Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol
2011;716:157–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21318905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber H, Müller D, Müller M, et al. . 
Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery. J Biomol Screen
2014;19:1350–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25260782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asquith CRM, Maffuid KA, Laitinen T, et al. . 
Targeting an EGFR water network with 4-Anilinoquin(az)oline inhibitors for chordoma. ChemMedChem
2019;14:1693–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31424613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo T, Ma S.. 
Recent advances in the discovery of multitargeted tyrosine kinase inhibitors as anticancer agents. ChemMedChem
2021;16:600–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33179854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asquith CRM, Naegeli KM, East MP, et al. . 
Design of a cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in chordoma. J Med Chem
2019;62:4772–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30973735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aziz MW, Kamal AM, Mohamed KO, et al. . 
Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines. Bioorg Med Chem Lett
2021;41:127987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33771586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui Z, Chen S, Wang Y, et al. . 
Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. Eur J Med Chem
2017;136:372–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28525838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>To C, Jang J, Chen T, et al. . 
Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov
2019;9:926–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6664433</ArticleId>
            <ArticleId IdType="pubmed">31092401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minnelli C, Laudadio E, Mobbili G, et al. . 
Conformational insight on WT- and mutated-EGFR receptor activation and inhibition by epigallocatechin-3-Gallate: over a rational basis for the design of selective non-small-cell lung anticancer agents. Int J Mol Sci
2020;21:1721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7084708</ArticleId>
            <ArticleId IdType="pubmed">32138321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leelananda SP, Lindert S.. 
Computational methods in drug discovery. Beilstein J Org Chem
2016;12:2694–718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5238551</ArticleId>
            <ArticleId IdType="pubmed">28144341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darney K, Lautz LS, Bechaux C, et al. . 
Human variability in polymorphic CYP2D6 metabolism: implications for the risk assessment of chemicals in food and emerging designer drugs. Environ Int
2021;156:106760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34256299</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
